Review article: biological drugs in Crohn's disease
Author:
- 31 August 2006
- journal article
- review article
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 24 (s3) , 80-89
Abstract
Biological drugs have opened new therapeutic horizons for treating Crohn's disease (CD), but have also brought with them issues related to immunogenicity, long-term efficacy, safety and cost. At present, inhibitors tumour necrosis factor and adhesion molecules are the most advanced in use and development. When treating luminal disease with infliximab, two-thirds of patients respond initially. The ACCENT 1 study demonstrated that 28% of initial responders are in remission for 1 year. Infliximab has also had a major impact on the management of Crohn's anorectal fistulas. The ACCENT 2 study demonstrated initial response in two-thirds of patients. One-fifth of all treated patients were healed at 1 year. Infliximab diminished the need for further surgery. Magnetic resonance imaging scanning allows the extent of deep healing to be assessed and may influence the duration of treatment. The Mayo Clinic experience in 500 patients demonstrated 6% serious adverse events related to infliximab. The TREAT registry will provide long-term safety data on a larger group of patients. Concurrent immunosuppressive drugs and pre-infusion steroids can decrease antibody formation to infliximab. Screening for tuberculosis (TB) diminishes the rate of TB activation. Biological drugs can offer great therapeutic benefit, but their use must be considered in context.Keywords
This publication has 22 references indexed in Scilit:
- Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's diseaseAlimentary Pharmacology & Therapeutics, 2005
- A Randomized, Placebo-Controlled Trial of Certolizumab Pegol (CDP870) for Treatment of Crohn’s DiseaseGastroenterology, 2005
- Progressive Multifocal Leukoencephalopathy after Natalizumab Therapy for Crohn's DiseaseNew England Journal of Medicine, 2005
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Autoimmunity associated with anti-tumor necrosis factor α treatment in Crohn’s disease: a prospective cohort studyGastroenterology, 2003
- Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's DiseaseNew England Journal of Medicine, 2003
- Treatment of active Crohn's disease with onercept (recombinant human soluble p55 tumour necrosis factor receptor): results of a randomized, open‐label, pilot studyAlimentary Pharmacology & Therapeutics, 2003
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- A controlled double blind study of azathioprine in the management of Crohn's disease.Gut, 1995